Despite the convincing efficacy of later-line IPI/NIVO in metastatic MCC patients who showed primary resistance to PD-L1 inhibition, the recently reported ORR of 100% to 1st line IPI/NIVO in patients with advanced MCC by Kim et al. Here, CD274 is linked to Merkel cell skin cancer.